Skip to main content
SpringerLink
Log in

Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

Clinical and Translational Oncology volume 20, pages 1467–1473 (2018)Cite this article

Abstract

Purpose

The aim of this phase II study was to evaluate the activity and safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy in unresectable locally advanced stage III non-small cell lung cancer (NSCLC). The primary endpoint was the objective response rate (ORR). Secondary objectives included toxicity profile, progression-free survival (PFS), and overall survival (OS).

Materials and methods

A total of 48 NSCLC patients were enrolled (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma). Patients received three cycles of chemotherapy every 21 days [intravenous cisplatin 80 mg/m2 and intravenous vinorelbine 25 mg/m2 on day 1 and oral vinorelbine on day 8 (60 mg/m2)] concurrent with radiotherapy (66 Gy, administered at 1.8 Gy per day, five consecutive days per week).

Results

ORR was 79.2% (72.9% showing partial response and 6.3% showing complete response). With a median follow-up of 20.7 months, median PFS was 12 months and median OS was 36 months. Grade 3/4 toxicities were: neutropenia (14.5%), anaemia (6.2%), vomiting (2%), and oesophagitis (4.2%). No toxic deaths were reported.

Conclusion

This combined regimen shows efficacy and a manageable safety profile. PFS and OS outcomes are encouraging and warrant further research.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):1–21. https://doi.org/10.1093/annonc/mdx222.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.

    Article  PubMed  Google Scholar 

  3. Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, et al. Management of stage III non-small cell lung cancer. Semin Oncol. 2017;44(3):163–77. https://doi.org/10.1053/j.seminoncol.2017.10.009.

    Article  PubMed  Google Scholar 

  4. Auperin A, Le Pechoux C, Pignon JP, Koning C, Jeremic B, Clamon G, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17(3):473–83. https://doi.org/10.1093/annonc/mdj117.

    Article  CAS  PubMed  Google Scholar 

  5. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90. https://doi.org/10.1200/jco.2009.26.2543.

    Article  CAS  PubMed  Google Scholar 

  6. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60. https://doi.org/10.1093/jnci/djr325.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–9. https://doi.org/10.1200/jco.1999.17.9.2692.

    Article  CAS  PubMed  Google Scholar 

  8. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, et al. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017;3(8):1120–9. https://doi.org/10.1001/jamaoncol.2016.4280.

    Article  PubMed  Google Scholar 

  9. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer (Amsterdam, Netherlands). 2004;46(1):87–98. https://doi.org/10.1016/j.lungcan.2004.03.004.

    Article  Google Scholar 

  10. O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6:140. https://doi.org/10.1002/14651858.cd002140.pub3.

    Article  Google Scholar 

  11. Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer (Amsterdam, Netherlands). 2005;48(1):129–35. https://doi.org/10.1016/j.lungcan.2004.10.006.

    Article  Google Scholar 

  12. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777–83. https://doi.org/10.1093/annonc/mdx009.

    Article  CAS  PubMed  Google Scholar 

  13. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953–62. https://doi.org/10.1200/jco.2015.64.8824.

    Article  CAS  PubMed  Google Scholar 

  14. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20(20):4191–8. https://doi.org/10.1200/jco.2002.03.054.

    Article  CAS  PubMed  Google Scholar 

  15. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001;12(11):1643–9.

    Article  CAS  PubMed  Google Scholar 

  16. Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol. 2003;14(11):1634–9.

    Article  CAS  PubMed  Google Scholar 

  17. Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol. 2001;12(10):1375–81.

    Article  CAS  PubMed  Google Scholar 

  18. Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660–6. https://doi.org/10.1200/jco.2014.60.0130.

    Article  CAS  PubMed  Google Scholar 

  19. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99. https://doi.org/10.1016/s1470-2045(14)71207-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol. 2008;3(9):994–1002. https://doi.org/10.1097/JTO.0b013e31818396cb.

    Article  PubMed  Google Scholar 

  21. Juan O, Sanchez-Hernandez A, Vazquez S, Casal J, Firvida JL, Aparisi F, et al. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014;34(4):1959–66.

    CAS  PubMed  Google Scholar 

  22. Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT–A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192(4):216–22. https://doi.org/10.1007/s00066-016-0941-8.

    Article  PubMed  Google Scholar 

  23. Singhal N, Mislang A, Karapetis CS, Stephens S, Borg M, Woodman RJ, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anticancer Drugs. 2015;26(10):1083–8. https://doi.org/10.1097/cad.0000000000000291.

    Article  CAS  PubMed  Google Scholar 

  24. Sobin LHGM, Wittekind CH. International union against cancer (UICC) TNM classification of malignant tumors. 7th ed. Oxford: Wiley-Blackwell; 2009.

    Google Scholar 

Download references

Acknowledgements

Medical writing support was provided by Dr. Almudena Fuster-Matanzo of Medical Statistics Consulting S.L. (Valencia).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Clara Campoamor 341, 36312, Vigo, Spain

    M. Costa Rivas, G. Huidobro Vence, M. Lázaro Quintela & J. Casal Rubio

  2. Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain

    J. L. Fírvida Pérez

  3. Department of Medical Oncology, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain

    B. Campos Balea & S. Vázquez Estevez

  4. Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

    J. García Gonzalez

  5. Department of Radiation Oncology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain

    M. Caeiro Muñoz

  6. Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

    B. Taboada Valladares

  7. Department of Radiation Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain

    J. E. Castro Gómez

  8. Department of Medical Oncology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain

    F. J. Afonso Afonso

  9. Department of Medical Oncology, Complexo Hospitalario de Pontevedra, Pontevedra, Spain

    C. Azpitarte Raposeiras

  10. Department of Medical Oncology, Centro Oncológico de Galicia, A Coruña, Spain

    M. Amenedo Gancedo

Authors
  1. M. Costa Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Huidobro Vence
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. L. Fírvida Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Campos Balea
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. García Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Lázaro Quintela
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Caeiro Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Taboada Valladares
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. E. Castro Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Vázquez Estevez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F. J. Afonso Afonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Azpitarte Raposeiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Amenedo Gancedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. Casal Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Casal Rubio.

Ethics declarations

Conflict of interest

The authors had no conflict of interest in this study.

Ethical approval

The protocol of this trial was approved by the ethics committee of each participating hospital and met the ethical principles stated in the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Costa Rivas, M., Huidobro Vence, G., Fírvida Pérez, J.L. et al. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol 20, 1467–1473 (2018). https://doi.org/10.1007/s12094-018-1880-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1880-x

Keywords

search

Navigation